Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts. It is focused on the development and commercialization of therapies for glaucoma and other serious diseases of the eye. The company's lead product candidate is Trabodenoson, formerly known as INO-8875, which is in Phase III clinical trials for lowering IOP. Trabodenoson has completed Phase 1, 2, and 3 clinical trials in subjects with OHT and POAG. Inotek was founded in 1999.